Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
The recently discovered Sulf2 enzyme acts to modify heparan sulfate (HS) associated with cell surface and extracellular matrix proteoglycans. This remodeling affects cellular recognition of growth factor families including transforming growth factors, vascular endothelial growth factors, and fibroblast growth factors. Detailed structural information on the HS domain context required for Sulf2 activity is lacking due to analytical challenges. Such information is essential to understanding the functional roles of Sulf2 enzymes as a function of tissue location and temporal changes in the growth environment (development and disease).
Over the past year we have use d the LC/MS platform to profile changes to HS structure mediated by recombinant Sulf2 enzyme. Data were collected by digesting HS from different bovine organs with Sulf2 and then treating with lyase enzymes. Exhaustive depolymerization followed by LC/MS extended the information on the disaccharide sites recognized by Sulf enzymes to include 2 sites not previously identified. This work was published recently (1).
In continuing work, porcine intestine mucosa HS was partially digested by heparin lyases I and III. HS oligosaccharides of degree of polymerization of 6-8 (dp6-8) were fractionated by SEC and collected. Part of the faction was treated with recombinant HSulf2 provided by Shire Pharmaceuticals. An equal quantity was treated with digestion buffer only as control. Both HSulf2 treated and control dp6-8 fractions were analyzed by a custom packed hydrophilic interaction chromatography HPLC-chip with pulsed make-up flow online with an Agilent 6520 QTOF. Those oligosaccharides exhibiting pronounced change with HSulf2 treatment were subjected to LC-MS/MS, with sulfolane pulsed at the corresponding retention time to elevate their charge states for better tandem MS.
Sulfs act on a subset of 6O-sulfates within HS chains. Our previously study of HSulf2 treatment followed by exhaustive heparin lyase depolymerization has shown that HSulf2 cleaves 6O-sulfate in the non-reducing end as well. However, due to the lack of structurally defined HS oligosaccharides, the elucidation of structural specificity of HSulf2 remains a challenge. In this study, we used oligosaccharides with reasonable lengths, of which isomeric profiles were simplified by lyase specificity, to discern the substrate structural preferences of HSulf2.
HSulf2 acts preferentially on highly sulfated dp6-8 with 0-1 acetate group. At the same time, the abundance of relatively low sulfated dp6-8 increased as the products by HSulf2. The average sulfation degree decreased more for dp6-8 with zero acetate than for those with one acetate group. Although dp6-8 with 2 acetate groups were highly sulfated and contain 6O-sulfation, HSulf2 did not change the profiles of dp6-8 with 2 acetate groups, suggesting its preference for few acetates and highly sulfated oligosaccharides.
Since only 6O-sulfation is cleaved by HSulf2, only certain isomers were affected and this was reflected by the chromatographic peak shape change of the extracted ion chromatograms (EICs). Those dp6-8 that were suspected to experience these changes were chosen as targets for tandem MS. A customized pulsed make-up flow HPLC-chip was used to pulsed sulfolane during the elution time of the target precursors to enhance their charge states for more informative tandem mass spectra. Although these tandem mass spectra seem to look similar for entire EIC peak range and entire collision energy range, by careful selection of retention time windows and collision energy, the spectra differences were made more evident, suggesting a subset of the oligosaccharides have been processed and HSulf2. These tandem mass spectra have the potential to provide more structural information of the substrate specificity of HSulf2.
1. Staples, G. O., Shi, X., and Zaia, J. (2011) Glycomics Analysis of Mammalian Heparan Sulfates Modified by the Human Extracellular Sulfatase HSulf2, PLoS ONE 6, e16689.
Public Health Relevance Statement
Data not available.
NIH Spending Category
Biotechnology
Project Terms
AcetatesAffectBiologyBuffersCattleCell surfaceChargeChromatographyCleaved cellCustomDataDevelopmentDigestionDisaccharidesDiseaseEnvironmentEnzymesExhibitsExtracellular MatrixFamilyFamily suidaeFibroblast Growth FactorFundingGrantGrowthGrowth FactorHeparin LyaseHeparitin SulfateHigh Pressure Liquid ChromatographyHumanInorganic SulfatesIntestinesIonsIsomerismLengthLocationLyaseMass Spectrum AnalysisMediatingMedicineMucous MembraneNational Center for Research ResourcesOligosaccharidesOrganPharmacologic SubstancePhysiologic pulsePrincipal InvestigatorProcessProteoglycanPublishingRecombinantsResearchResearch InfrastructureResourcesRoleShapesSiteSourceSpecificityStructureSubstrate SpecificitySulfatasesTimeTissuesTransforming Growth FactorsUnited States National Institutes of HealthUnspecified or Sulfate Ion SulfatesVascular Endothelial Growth FactorsWorkcostdepolymerizationexperienceextracellularliquid chromatography mass spectrometrypolymerizationpreferencesulfation
No Sub Projects information available for 5P41RR010888-15 5135
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P41RR010888-15 5135
Patents
No Patents information available for 5P41RR010888-15 5135
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P41RR010888-15 5135
Clinical Studies
No Clinical Studies information available for 5P41RR010888-15 5135
News and More
Related News Releases
No news release information available for 5P41RR010888-15 5135
History
No Historical information available for 5P41RR010888-15 5135
Similar Projects
No Similar Projects information available for 5P41RR010888-15 5135